(A) Yeast- to hyphal-phase transition. (B) Downregulation of epithelial TLR4 expression. (C) Shielding of PAMP from PRR recognition. (D) Inhibition or degradation of complement system. (E) Inhibition of phagolysosome formation. (F) Modulation of T cell function.